Dr. Daniel Riskin, MD

NPI: 1356479463
Total Payments
$42,285
2024 Payments
$141.27
Companies
1
Transactions
37

Payment Breakdown by Category

Consulting$31,075 (73.5%)
Travel$10,275 (24.3%)
Food & Beverage$651.84 (1.5%)
Research$282.77 (0.7%)
Other$0.00 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $31,075 9 73.5%
Travel and Lodging $10,275 12 24.3%
Food and Beverage $651.84 14 1.5%
Unspecified $282.77 2 0.7%

Payments by Type

General
$42,002
35 transactions
Research
$282.77
2 transactions

Top Paying Companies

Company Total Records Latest Year
Amgen Inc. $42,285 37 $0 (2024)

Payment History by Year

Year Amount Transactions Top Company
2024 $141.27 1 Amgen Inc. ($141.27)
2020 $7,370 14 Amgen Inc. ($7,370)
2019 $24,703 15 Amgen Inc. ($24,703)
2018 $9,612 4 Amgen Inc. ($9,612)
2017 $459.70 3 Amgen Inc. ($459.70)

All Payment Transactions

37 individual payment records from CMS Open Payments — Page 1 of 2

Date Company Product Nature Form Amount Type
12/04/2024 Amgen Inc. TEZSPIRE (Biological) In-kind items and services $141.27 Research
Study: Tezepelumab 20210017 INSIGHTS: Improving SOC in asthma through advanced real world data analytics • Category: Inflammation
11/18/2020 Amgen Inc. In-kind items and services $141.50 Research
Study: Enabling Advanced Real-World Evidence in Heart Failure: A Pilot Study Defining Preferred Approaches
03/04/2020 Amgen Inc. EVENITY (Biological), Prolia, Repatha Consulting Fee Cash or cash equivalent $4,950.00 General
Category: Bone Health
03/04/2020 Amgen Inc. EVENITY (Biological), Prolia, Repatha Consulting Fee Cash or cash equivalent $1,100.00 General
Category: Bone Health
02/22/2020 Amgen Inc. Travel and Lodging In-kind items and services $129.11 General
02/22/2020 Amgen Inc. Food and Beverage In-kind items and services $45.05 General
02/22/2020 Amgen Inc. Food and Beverage In-kind items and services $23.12 General
02/21/2020 Amgen Inc. Travel and Lodging In-kind items and services $325.66 General
02/21/2020 Amgen Inc. Travel and Lodging In-kind items and services $283.37 General
02/21/2020 Amgen Inc. Travel and Lodging In-kind items and services $199.84 General
02/21/2020 Amgen Inc. Food and Beverage In-kind items and services $100.00 General
02/21/2020 Amgen Inc. Food and Beverage In-kind items and services $25.99 General
02/21/2020 Amgen Inc. Food and Beverage In-kind items and services $20.55 General
02/07/2020 Amgen Inc. Repatha (Biological) Food and Beverage In-kind items and services $8.89 General
Category: Cardiology
02/06/2020 Amgen Inc. Repatha (Biological) Food and Beverage In-kind items and services $16.50 General
Category: Cardiology
09/28/2019 Amgen Inc. Repatha (Biological) Food and Beverage In-kind items and services $20.94 General
Category: Cardiology
09/27/2019 Amgen Inc. Repatha (Biological) Food and Beverage In-kind items and services $7.81 General
Category: Cardiology
08/07/2019 Amgen Inc. Repatha (Biological) Food and Beverage In-kind items and services $65.26 General
Category: Cardiology
07/15/2019 Amgen Inc. Consulting Fee Cash or cash equivalent $4,400.00 General
07/15/2019 Amgen Inc. Consulting Fee Cash or cash equivalent $1,650.00 General
07/11/2019 Amgen Inc. Repatha (Biological) Consulting Fee Cash or cash equivalent $4,400.00 General
Category: Cardiology
07/11/2019 Amgen Inc. Repatha (Biological) Consulting Fee Cash or cash equivalent $2,750.00 General
Category: Cardiology
07/11/2019 Amgen Inc. Repatha (Biological) Consulting Fee Cash or cash equivalent $2,750.00 General
Category: Cardiology
07/11/2019 Amgen Inc. Repatha (Biological) Travel and Lodging Cash or cash equivalent $706.60 General
Category: Cardiology
07/11/2019 Amgen Inc. Repatha (Biological) Travel and Lodging Cash or cash equivalent $83.14 General
Category: Cardiology

Research Studies & Clinical Trials

Study Name Company Amount Records
Enabling Advanced Real-World Evidence in Heart Failure: A Pilot Study Defining Preferred Approaches Amgen Inc. $141.50 1
Tezepelumab 20210017 INSIGHTS: Improving SOC in asthma through advanced real world data analytics Amgen Inc. $141.27 1

About Dr. Daniel Riskin, MD

Dr. Daniel Riskin, MD is a Surgery healthcare provider based in San Jose, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/01/2007. The National Provider Identifier (NPI) number assigned to this provider is 1356479463.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Riskin, MD has received a total of $42,285 in payments from pharmaceutical and medical device companies, with $141.27 received in 2024. These payments were reported across 37 transactions from 1 company. The most common payment nature is "Consulting Fee" ($31,075).

Practice Information

  • Specialty Surgery
  • Location San Jose, CA
  • Active Since 03/01/2007
  • Last Updated 01/31/2022
  • Taxonomy Code 208600000X
  • Entity Type Individual
  • NPI Number 1356479463

Products in Payments

  • Repatha (Biological) $28,749
  • EVENITY (Biological) $6,050
  • TEZSPIRE (Biological) $141.27

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Surgery Doctors in San Jose